Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer

References

• ZhangHApatinib for molecular targeted therapy in tumorDrug Des Devel Ther2015960756081
   PubMed Web of Science ®Google Scholar
• RussoAFranchinaTRicciardiGRA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectivesOncotarget2015629268142682526308162
   PubMedGoogle Scholar
• LiuYBZhaoYQinYXDuXHWangQLyuJXA novel micro-fluidic device that integrates nucleic acid extraction, amplification, and detection to identify an EGFR mutation in lung cancer tissuesRSC Adv20166161339913406
   Web of Science ®Google Scholar
• TiseoMBartolottiMGelsominoFBordiPEmerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)Drug Des Devel Ther201048198
   PubMed Web of Science ®Google Scholar
• ZhangQWangZGuoJComparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancerOnco Targets Ther2015889389825945061
   PubMed Web of Science ®Google Scholar
• VilladolidJErsekJLFongMKSiriannoLStoryESManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceTransl Lung Cancer Res20154557658326629426
   PubMedGoogle Scholar
• ErcanDChoiHGYunCHEGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitorsClin Cancer Res201521173913392325948633
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• RamalingamSSBlackhallFKrzakowskiMRandomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerJ Clin Oncol201230273337334422753918
   PubMed Web of Science ®Google Scholar
• CrossDAAshtonSEGhiorghiuSAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerCancer Discov2014491046106124893891
   PubMed Web of Science ®Google Scholar
• PirkerRThird-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerCurr Opin Oncol201628211512126720671
   PubMed Web of Science ®Google Scholar
• GreigSLOsimertinib: first global approvalDrugs201676226327326729184
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• ShiYZhangLLiuXIcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncol2013141095396123948351
   PubMed Web of Science ®Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol201028253965397220679611
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A2005102217665767015897464
   PubMed Web of Science ®Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKGaleCMPF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res20076724119241193218089823
   PubMed Web of Science ®Google Scholar
• JännePAOuSHKimDWDacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialLancet Oncol201415131433144125456362
   PubMed Web of Science ®Google Scholar
• EllisPMShepherdFAMillwardMNCIC CTGAustralasian Lung Cancer Trials GroupNCI Naples Clinical Trials UnitDacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trialLancet Oncol201415121379138825439692
   PubMed Web of Science ®Google Scholar
• JiangTZhouCClinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancerTransl Lung Cancer Res20143637037225806323
   PubMedGoogle Scholar
• YosaatmadjaYSilvaSDicksonJMBinding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedJ Struct Biol2015192353954426522274
   PubMed Web of Science ®Google Scholar
• JännePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• YangJRamalingamSSJännePACantariniMMitsudomiTLBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) resultsJ Thorac Oncol2016114 supplS152S153
   Web of Science ®Google Scholar
• WalterAOSjinRTHaringsmaHJDiscovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCCancer Discov20133121404141524065731
   PubMed Web of Science ®Google Scholar
• SequistLVSoriaJCGoldmanJWRociletinib in EGFR-mutated non-small-cell lung cancerN Engl J Med2015372181700170925923550
   PubMed Web of Science ®Google Scholar
• ParkKLeeJ-SLeeKHUpdated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI)J Clin Oncol20153315 suppl8084
   Google Scholar
• GüntherMJuchumMKelterGFiebigHLauferSLung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutantAngew Chem Int Ed Engl20165536108901089427466205
   PubMed Web of Science ®Google Scholar